Changes in Hong Kong stocks | Zaiding Pharmaceutical (09688) rose more than 5%, and the core pipeline ushered in intensive catalytic innovation, which will become the core driving force for the next stage of growth

The Zhitong Finance App learned that Zaiding Pharmaceutical (09688) has increased by more than 5%, and its stock price has already risen by more than 30% after the results. As of press release, it rose 5.02% to HK$19.46, with a turnover of HK$304 million.

According to the news, Zaiding Pharmaceutical achieved total revenue of US$106.3 million and net product revenue of US$105.8 million in the second quarter of this year, up 11% month-on-month, thanks to Zele's steady performance and continued growth in sales of Agamod. It is worth mentioning that Du Ying, founder, chairman and CEO of Zaiding Pharmaceutical, said that over the past few years, the company has gradually grown from bringing innovative drugs to Chinese patients to a global biopharmaceutical company developing differentiated drugs for patients around the world. Currently, the company's innovation pipeline is rapidly maturing, and innovation will increasingly become the core driving force for the next stage of growth.

CITIC Construction Investment pointed out that the company's independent R&D assets are gradually entering the clinical value verification stage, and the core self-research pipeline is expected to usher in intensive data readings and key R&D progress within the year. Important catalysts for the second half of 2026 include: publication of Zoci (ZL-1310, DLL3 ADC) first-line small cell lung cancer (1 LSCLC) combined treatment data, promotion of 1L SCLC and extrapulmonary neuroendocrine cancer (ep NE C) registration development; and publication of the first human data on ZL-1503 (IL-13×IL-31Rα double antibody).